CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
5.50
0.00 (0.00%)
Aug 14, 2025, 12:00 PM - Market open
CureVac Employees
As of December 31, 2024, CureVac had 983 total employees, including 825 full-time and 158 part-time employees. The number of employees decreased by 189 or -16.13% compared to the previous year.
Employees
983
Change (1Y)
-189
Growth (1Y)
-16.13%
Revenue / Employee
$575,829
Profits / Employee
$198,637
Market Cap
1.24B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 983 | -189 | -16.13% |
| Dec 31, 2023 | 1,172 | 123 | 11.73% |
| Dec 31, 2022 | 1,049 | 165 | 18.67% |
| Dec 31, 2021 | 884 | 330 | 59.57% |
| Dec 31, 2020 | 554 | 100 | 22.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CVAC News
- 6 days ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters
- 7 weeks ago - CureVac Announces Voting Results of General Meeting - Accesswire
- 2 months ago - Top Stock Movers Now: Oracle, Boeing, CureVac, and More - Investopedia
- 2 months ago - BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
- 2 months ago - BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising. - Barrons
- 2 months ago - BioNTech to acquire CureVac in $1.25 billion all-stock deal - Reuters
- 3 months ago - CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - Accesswire
- 3 months ago - CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE - Accesswire